GlassScriptPhysician profile
Michael J Reddy
NPI 1386647444
$3,148.30
in general payments reported to CMS, 2019-2025
31 companies · $604 in 2025
The $604 reported for 2025 was more than what 75% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $398 · 2023: $1,096 · 2024: $1,051 · 2025: $604.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,751.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,750.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $355.07 | 2023-2025 | |
| Axonics, INC. | $278.26 | 2023-2024 | Bulkamid, Axonics |
| 180 Medical, INC. | $250.02 | 2022-2024 | Gentlecath Glide, Gentlecath, Speedicath |
| Merck Sharp & Dohme LLC | $202.69 | 2022-2025 | Keytruda, Lynparza |
| Astellas Pharma US INC | $199.95 | 2022-2025 | Myrbetriq, Xtandi |
| Bayer Healthcare Pharmaceuticals INC. | $195.64 | 2022-2025 | |
| Janssen Biotech, INC. | $187.53 | 2022-2025 | Erleada |
| Antares Pharma, INC. | $169.66 | 2024-2025 | Xyosted |
| Tolmar, INC. | $161.29 | 2023-2025 | Jatenzo, Eligard |
| Urogen Pharma, INC. | $127.27 | 2022-2024 | Jelmyto |
| Alnylam Pharmaceuticals INC. | $117.07 | 2023-2025 | Givlaari |
| Dendreon Pharmaceuticals LLC | $97.41 | 2024 | Provenge |
| Sumitomo Pharma America, INC. | $82.54 | 2023-2025 | Gemtesa, Orgovyx |
| Medtronic, INC. | $81.40 | 2023-2025 | Interstim, Altaviva |
| Ferring Pharmaceuticals INC. | $61.86 | 2024-2025 | Adstiladrin |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Urovant Sciences INC | $60.39 | 2022 | |
| Endo Pharmaceuticals INC. | $59.81 | 2023-2024 | Xiaflex |
| Teleflex LLC | $58.57 | 2022 | |
| Halozyme INC | $54.87 | 2023 | |
| Myriad Genetic Laboratories, INC. | $46.33 | 2023-2024 | Prolaris |
| Endo USA, INC. | $37.34 | 2024-2025 | Xiaflex |
| Pfizer INC. | $35.91 | 2023-2025 | |
| Boston Scientific Corporation | $34.90 | 2025 | Axonics |
| Cardinal Health 414 LLC | $33.90 | 2023-2024 | |
| Astrazeneca Pharmaceuticals LP | $31.06 | 2023-2024 | Lynparza |
| Telix Pharmaceuticals | $29.28 | 2024 | Illuccix |
| Olympus America INC. | $23.00 | 2024 | Itind System |
| Foundation Medicine, INC. | $21.53 | 2023 | |
| Accord Healthcare, INC. | $19.25 | 2024 | |
| Agiliti Surgical, INC. | $19.21 | 2023 | Sonablate |
| Coloplast Corp | $15.29 | 2023 | Speedicath |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Reddy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.